

Genveon İlaç starts production by acquiring the production facility located in Gebze

As one of the fastest growing companies of the sector in the recent years with its wide range of portfolio consisting of original, equivalent and OTC pharmaceutical products in the acute and chronic markets, Generica İlaç announced that they've concluded an agreement with Novartis to purchase one of the two production facilities located in Gebze.

“Our process of continuously introducing new products to the Turkish market will expedite with this acquisition”

Alp Karaağaç, Founder and Chairman of the Board of Directors of Generica İlaç, is a member of a family that has been in the Turkish pharmaceutical industry for 60 years. Karaağaç emphasized that; with this acquisition, the company aims to add new equivalent and OTC products to their portfolio and the market, and continued:

“We’re in the process of taking over the torch of production in one of the production facilities of global pharmaceutical leader Novartis. We’re happy to incorporate an excellent production facility with a team of experts which will take Generica further. This acquisition will bring a high-quality production that will meet and even exceed the expectations of all our stakeholders. We will resume production with the plant workers in a pleasant work environment, and provide job opportunities to the young generation as well. We’ll add significant values to Turkish pharmaceutical R&D. With this facility that has global quality standards, our most important objective is to maintain sustainable excellency in production, and engage in production for many countries, Europe in particular. This collaboration and technology transfer we have established with a global leader such as Novartis is a major achievement for the Turkish pharmaceutical sector”.

“Our primary focus at the planned transfer stage of our production facility was the employment of our employees and continued production process”

Dr. Altan Demirdere, President of Novartis Group Turkey, said the following about the planning sale of the production facility by transfer: “We’re still consolidating the 4 existing facilities located in Turkey and reducing them to 2. Our aim is to increase our productivity. Our total production in the facilities located in Turkey and our export will increasingly continue in the upcoming years as well. As Novartis, our priority is our patients, employees, and our responsibilities towards the community we’re in. Generica will continue to provide uninterrupted pharmaceutical products to the worldwide health system and patients by continuing to produce and supply for Novartis - *who has export operations to 67 counties including the EU, Japan, Canada, and Australia* - in its Gebze production facility equipped with Solid, Pellet, HGC, Semi-Solid, Liquid, and Suppository technologies.

Alp Karaağaç stated that following the transfer, they will invest in the facility and pursue business development opportunities and focus on export to optimize the production and extend the customer base, and added:

“We’re aiming for an uninterrupted transition for all employees, patients, customers, business partners and other stakeholders following the completion of the transfer”.

About Generica İlaç

As one of the fastest growing companies of the sector in the recent years, Generica İlaç is a fast-growing pharmaceutical company which continuously introduces new products to the Turkish market with its wide range of portfolio composed of original, equivalent and OTC pharmaceutical products in the acute and chronic markets. The company develops value-added pharmaceutical products in various forms and formulations with its R&D facility established in 2010. Providing services for many therapeutic areas with an effective marketing approach and wide sales force, Generica will continue to create significant values for patient care and Turkish Medicine.